AR064262A1 - Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato - Google Patents
Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonatoInfo
- Publication number
- AR064262A1 AR064262A1 ARP070105120A ARP070105120A AR064262A1 AR 064262 A1 AR064262 A1 AR 064262A1 AR P070105120 A ARP070105120 A AR P070105120A AR P070105120 A ARP070105120 A AR P070105120A AR 064262 A1 AR064262 A1 AR 064262A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally
- liquid pharmaceutical
- amount
- therapeutic use
- bisphosphonate
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000002131 composite material Substances 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 4
- 229940122361 Bisphosphonate Drugs 0.000 abstract 3
- 150000004663 bisphosphonates Chemical class 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 238000011200 topical administration Methods 0.000 abstract 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract 2
- 235000011187 glycerol Nutrition 0.000 abstract 2
- 239000008240 homogeneous mixture Substances 0.000 abstract 2
- 239000003906 humectant Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- -1 bisphosphonate compound Chemical class 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000003349 gelling agent Substances 0.000 abstract 1
- 239000002085 irritant Substances 0.000 abstract 1
- 231100000021 irritant Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 231100000344 non-irritating Toxicity 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composiciones farmacéuticas líquidas que comprenden un compuesto bisfosfonato para administracion topica. Reivindicacion 1: Una composicion farmacéutica líquida para administracion a la piel humana que comprende: (1) una cantidad efectiva para uso terapéutico de al menos un bisfosfonato (ii) opcionalmente, una cantidad irritante de al menos un humectante con preferencia glicerina, (iii) opcionalmente, al menos un alcohol alifático de cadena rota, (iv) opcionalmente, al menos un tensioactivo y (v) agua, donde dicha composicion: es una mezcla estable, microscopicamente homogénea, tiene un pH de entre 4,0 y 8,5 y no contienen ningun gelante y es no oclusiva y no forma película. Reivindicacion 16: El dispositivo de la cualquiera de las Reivindicaciones 12-15, donde el aplicador comprende un aplicador seleccionado del grupo que consiste en un gotero, pipeta, hisopo, cepillo, pano, almohadilla, esponja y soporte solido. Reivindicacion 22: Un método para tratar un trastorno relacionado con los huesos, que comprende la administracion topica a una superficie de la piel de un paciente necesitado de la misma, de una cantidad efectiva para uso terapéutico de una composicion farmacéutica líquida que comprende: (i) una cantidad efectiva para uso terapéutico de al menos un bisfosfonato, (ii) opcionalmente, una cantidad no irritante de al menos un humectante con preferencia glicerina, (iii) opcionalmente al menos un alcohol alifático de cadena corta, (iv) opcionalmente, al menos un tensioactivo y (v) agua donde dicha composicion : es una mezcla estable, microscopicamente homogénea, tiene un pH de entre 4,o y 8,5, no contiene ningun agente gelante, es no oclusiva y no forma película, y se adapta para administracion topica a la superficie de la piel.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86629406P | 2006-11-17 | 2006-11-17 | |
| US86630606P | 2006-11-17 | 2006-11-17 | |
| EP06291786A EP1923050A1 (en) | 2006-11-17 | 2006-11-17 | Liquid pharmaceutical compositions comprising a bisphosphonate compound |
| EP06291785A EP1923049A1 (en) | 2006-11-17 | 2006-11-17 | Pharmaceutical compositions comprising a bisphosphonate compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064262A1 true AR064262A1 (es) | 2009-03-25 |
Family
ID=38895592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105120A AR064262A1 (es) | 2006-11-17 | 2007-11-16 | Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato |
| ARP070105121A AR064263A1 (es) | 2006-11-17 | 2007-11-16 | Composiciones farmaceuticas que comprenden un compuesto bisfosfato |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105121A AR064263A1 (es) | 2006-11-17 | 2007-11-16 | Composiciones farmaceuticas que comprenden un compuesto bisfosfato |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20080182822A1 (es) |
| EP (2) | EP2114368A1 (es) |
| JP (2) | JP2010510195A (es) |
| AR (2) | AR064262A1 (es) |
| AU (2) | AU2007321109A1 (es) |
| CA (2) | CA2669489A1 (es) |
| IL (2) | IL198678A0 (es) |
| TW (2) | TW200831130A (es) |
| WO (2) | WO2008059059A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007321109A1 (en) * | 2006-11-17 | 2008-05-22 | Besins Healthcare | Liquid pharmaceutical compositions comprising a bisphosphonate compound |
| EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
| AU2010278860B2 (en) | 2009-07-31 | 2016-05-26 | Thar Pharma, Llc | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| US12377149B2 (en) | 2018-06-01 | 2025-08-05 | The University Of North Carolina At Chapel Hill | Injectable thermoresponsive hydrogels as a combinatory modality for controlled drug delivery, biomaterial implant and 3D printing bioink |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX21453A (es) * | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | Preparaciones farmaceuticas que se administran en forma topica. |
| MX21452A (es) * | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | Preparaciones farmaceuticas que se administran en forma topica. |
| GB9408775D0 (en) * | 1994-05-04 | 1994-06-22 | Ciba Geigy Ag | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
| JP3411690B2 (ja) * | 1994-09-21 | 2003-06-03 | 帝人株式会社 | 局所投与用アレンドロン酸ナトリウム製剤 |
| US6905701B2 (en) * | 1997-06-11 | 2005-06-14 | Umd, Inc. | Formulations for transmucosal vaginal delivery of bisphosphonates |
| WO2000028982A2 (en) * | 1998-11-19 | 2000-05-25 | The Board Of Trustees For The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
| US20050074487A1 (en) * | 1999-12-16 | 2005-04-07 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| JP2001253827A (ja) * | 2000-02-15 | 2001-09-18 | Pfizer Prod Inc | 骨粗鬆症を治療するための組成物および方法 |
| EP1284754B1 (en) * | 2000-05-05 | 2006-01-04 | F. Hoffmann-La Roche Ag | Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts |
| JP4394888B2 (ja) * | 2002-02-14 | 2010-01-06 | 救急薬品工業株式会社 | 経皮投与製剤 |
| KR20100063827A (ko) * | 2002-02-14 | 2010-06-11 | 규큐 야쿠힝 고교 가부시키가이샤 | 경피투여제제 |
| WO2005007100A2 (en) * | 2003-07-11 | 2005-01-27 | Macrochem Corporation | Pharmaceutical compositions for topical application |
| US20050119230A1 (en) * | 2003-09-18 | 2005-06-02 | Alexandra Glausch | Pharmaceutical products comprising bisphosphonated |
| MY141763A (en) * | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| CA2542753A1 (en) * | 2003-10-14 | 2005-04-28 | Dermatrends, Inc. | Enhancing transdermal administration of hydrophilic drugs |
| AU2007321109A1 (en) * | 2006-11-17 | 2008-05-22 | Besins Healthcare | Liquid pharmaceutical compositions comprising a bisphosphonate compound |
-
2007
- 2007-11-16 AU AU2007321109A patent/AU2007321109A1/en not_active Abandoned
- 2007-11-16 US US11/941,393 patent/US20080182822A1/en not_active Abandoned
- 2007-11-16 CA CA002669489A patent/CA2669489A1/en not_active Abandoned
- 2007-11-16 WO PCT/EP2007/062472 patent/WO2008059059A1/en not_active Ceased
- 2007-11-16 AR ARP070105120A patent/AR064262A1/es unknown
- 2007-11-16 JP JP2009536746A patent/JP2010510195A/ja active Pending
- 2007-11-16 US US11/941,417 patent/US20080167271A1/en not_active Abandoned
- 2007-11-16 AR ARP070105121A patent/AR064263A1/es unknown
- 2007-11-16 CA CA002669488A patent/CA2669488A1/en not_active Abandoned
- 2007-11-16 EP EP07847195A patent/EP2114368A1/en not_active Withdrawn
- 2007-11-16 EP EP07847196A patent/EP2088996A1/en not_active Withdrawn
- 2007-11-16 JP JP2009536745A patent/JP2010510194A/ja active Pending
- 2007-11-16 AU AU2007321108A patent/AU2007321108A1/en not_active Abandoned
- 2007-11-16 WO PCT/EP2007/062473 patent/WO2008059060A1/en not_active Ceased
- 2007-11-19 TW TW096143764A patent/TW200831130A/zh unknown
- 2007-11-19 TW TW096143765A patent/TW200829282A/zh unknown
-
2009
- 2009-05-11 IL IL198678A patent/IL198678A0/en unknown
- 2009-05-12 IL IL198698A patent/IL198698A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200829282A (en) | 2008-07-16 |
| EP2114368A1 (en) | 2009-11-11 |
| IL198678A0 (en) | 2010-02-17 |
| JP2010510194A (ja) | 2010-04-02 |
| WO2008059060A1 (en) | 2008-05-22 |
| EP2088996A1 (en) | 2009-08-19 |
| AU2007321109A1 (en) | 2008-05-22 |
| AU2007321109A2 (en) | 2009-06-11 |
| IL198698A0 (en) | 2010-02-17 |
| CA2669489A1 (en) | 2008-05-22 |
| WO2008059059A1 (en) | 2008-05-22 |
| AR064263A1 (es) | 2009-03-25 |
| US20080182822A1 (en) | 2008-07-31 |
| TW200831130A (en) | 2008-08-01 |
| AU2007321108A1 (en) | 2008-05-22 |
| US20080167271A1 (en) | 2008-07-10 |
| JP2010510195A (ja) | 2010-04-02 |
| CA2669488A1 (en) | 2008-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064262A1 (es) | Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato | |
| JP5144277B2 (ja) | 局所用生体付着性製剤 | |
| JP5731446B2 (ja) | 局所用生体付着性製剤 | |
| AR063201A1 (es) | Composiciones farmaceuticas de ropinirol y metodos de uso de las mismas | |
| BRPI0822162B8 (pt) | composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| SG156624A1 (en) | Organo-gel formulations for therapeutic applications | |
| AR055552A1 (es) | Preparacion topica refrescante para parches y metodos para utilizar la misma | |
| BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
| JP2016510807A5 (es) | ||
| PE20080523A1 (es) | Composiciones farmaceuticas topicas que comprenden un modificador de respuesta inmune | |
| CR6656A (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| AR029655A1 (es) | Mejoras en formulaciones en pasta | |
| CA2567575A1 (en) | Organo-gel formulations for therapeutic applications | |
| ES2137993T3 (es) | La utilizacion de glicerina para moderar el aporte transdermico de medicamentos. | |
| JP2009084289A (ja) | 体表面からの刺激性化合物の除去のための組成物およびキット | |
| AR053680A1 (es) | Composicion | |
| BRPI0509708B8 (pt) | espuma farmacêutica, composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbídeo e/ou triglicerídeos de cadeia média e uso | |
| JP2006502166A5 (es) | ||
| CL2004000899A1 (es) | Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion. | |
| ITMI932634A1 (it) | Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico | |
| PE20040548A1 (es) | Lamina revestida de adhesivo para administracion dermica de un inhibidor selectivo de ciclooxigenasa-2 | |
| CN1503655A (zh) | 糖摄取促进剂 | |
| AR064185A1 (es) | Composiciones y metodos para tratar las convulsiones | |
| ES2732892T3 (es) | Composición de tratamiento de hongos en las uñas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |